Fresenius Kabi
About Fresenius Kabi
Fresenius Kabi is a global health care company that specializes in lifesaving medicines and technologies for infusion, transfusion and clinical nutrition. The company’s products and services are used to help care for critically and chronically ill patients. Fresenius Kabi’s product portfolio comprises a comprehensive range of I.V. generic drugs, infusion therapies and clinical nutrition products as well as the medical devices for administering these products. Within transfusion technologies, Fresenius Kabi offers products for collection and processing of blood components and for therapeutic treatment of patient blood by apheresis systems.
87 articles about Fresenius Kabi
-
Fresenius Kabi Introduces Copay Assistance for Cancer Treatments Using Generic Medicines
4/13/2022
Fresenius Kabi announced today it has introduced KabiConnect, part of the KabiCare patient support program in the United States, to offer copay assistance for the company’s generic oncology medicines.
-
Insud Pharma and Fresenius Kabi combine efforts to accelerate the growth of mAbxience
3/31/2022
Insud Pharma announced that it has entered into an agreement with Fresenius Kabi.
-
Fresenius Kabi Receives U.S. Food and Drug Administration 510(k) Clearance for Wireless Agilia® Connect Infusion System with Vigilant® Software Suite-Vigilant® Master Med Technology
3/14/2022
Fresenius Kabi Receives U.S. Food and Drug Administration 510(k) Clearance for Wireless Agilia ® Connect Infusion System with Vigilant ® Software Suite-Vigilant ® Master Med Technology.
-
Fresenius Kabi Issues Voluntary Recall of Sodium Acetate Injection, USP Due to the Presence of Particulate Matter
3/7/2022
Fresenius Kabi USA is voluntarily recalling seven lots of Sodium Acetate Injection, USP, 400 mEq/100 mL (4 mEq/mL), 100 mL fill in a 100 mL vial to the user level due to the presence of particulate matter found in reserve and/or stability sample vials.
-
Omnicell and Fresenius Kabi Collaborate to Enhance Management of Controlled Substances in U.S. Hospitals
11/10/2021
Omnicell, Inc. and pharmacies, and Fresenius Kabi are collaborating to provide U.S. hospitals and health systems with innovative new pharmacy technology designed to support safety and efficiency in dispensing of controlled substances in patient care areas.
-
Fresenius Kabi Introduces New Simplist® Fentanyl Citrate Injection, USP 50 mcg per 1 mL in Ready-to-Administer Prefilled Syringe
7/6/2021
Fresenius Kabi announced today the U.S. introduction of Fentanyl Citrate Injection, USP 50 mcg per 1 mL in its proprietary Simplist ® ready-to-administer prefilled syringe.
-
Fresenius Kabi Receives Premier Supplier Legacy Award
6/21/2021
Fresenius Kabi announced today it has received a 2021 Supplier Legacy Award from Premier Inc. ( www.premierinc.com ), a leading health care improvement company.
-
Temsirolimus Injection Now Available from Fresenius Kabi
5/21/2021
Fresenius Kabi announced today the immediate availability of Temsirolimus Injection in the United States. Fresenius Kabi’s Temsirolimus Injection is supplied as a kit including one vial of 25 mg/mL Temsirolimus solution and one vial of diluent.
-
Fresenius Kabi Signs Exclusive U.S. Distribution Agreement with Corvida Medical for the HALO® Closed System Drug-Transfer Device
4/1/2021
Fresenius Kabi Signs Exclusive U.S. Distribution Agreement with Corvida Medical for the HALO ® Closed System Drug-Transfer Device Enhances Fresenius Kabi’s extensive offerings in oncology care
-
The cancer drugmaker pled guilty of violating the Federal Food, Drug and Cosmetic Act by failing to provide certain records to investigators in federal court.
-
Fresenius Kabi Issues Voluntary Nationwide Recall of Ketorolac Tromethamine Injection, USP Due to the Presence of Particulate Matter
1/8/2021
Fresenius Kabi USA is voluntarily recalling a single lot of Ketorolac Tromethamine Injection, USP, 30 mg/mL, 1 mL fill in a 2 mL amber vial to the user level due to the presence of particulate matter. Particulate matter was found in reserve sample vials. No adverse event reports have been received for the recalled lot, which was produced and sold in 2019. This press release features multimedia. View the full release
-
ScaleReady Launches With the Mission to Revolutionize T Cell Therapy Manufacturing
1/6/2021
ScaleReady’s mission is to make the business of cell and gene therapy practical and viable by providing the most simple, scalable and versatile manufacturing platform in the industry
-
Fresenius Kabi Announces Availability of Acetaminophen Injection for Intravenous use in Ready-to-Use freeflex® Bags
12/10/2020
Fresenius Kabi Announces Availability of Acetaminophen Injection for Intravenous use in Ready-to-Use free flex ® Bags Acetaminophen is an option for multimodal pain management in the perioperative period.
-
Fresenius Kabi and Kit Check Collaborate on RFID Compatibility
12/9/2020
Fresenius Kabi and Kit Check today announced the companies have entered into an agreement under which Fresenius Kabi +RFID™ medications will be read by the Kit Check inventory management solution. The collaboration signals both companies’ commitment to medication safety and quality patient care acr
-
Fresenius Kabi Launches Icatibant Injection to Treat Acute Attacks of Hereditary Angioedema in Adults
12/1/2020
Company’s first specialty drug is therapeutically equivalent to Firazyr ® and is a cost-effective generic alternative to currently marketed products for the treatment of acute attacks of hereditary angioedema Fresenius Kabi launches KabiCare patient support program in U.S. to promote access to essential medications
-
VFMCRP and Fresenius Kabi expand collaboration in nephrology in China with Veltassa® agreement
11/19/2020
Veltassa® is a well-tolerated1 and effective2 oral calcium potassium binder for the treatment of hyperkalemia supported by 12 month clinical data
-
Fresenius Kabi Introduces RFID Smart Labels for a Range of Essential Medications
8/18/2020
Fresenius Kabi announced it is introducing smart labels for a range of essential medications used in hospitals.
-
CORRECTING and REPLACING Fresenius Kabi Issues Voluntary Nationwide Recall of Two Lots of Dexmedetomidine Hydrochloride Injection Due to Cross-Contamination of Lidocaine
7/23/2020
The date under the "Expiration Date" column for the row associated with Batch Number 6122207 should read: 06/2021.
-
Premier Inc. ProvideGx™ Program Partners with Fresenius Kabi to Secure the Supply of Sedation Drug Essential for COVID-19 Care
7/13/2020
Premier Inc., through its ProvideGx™ program, has partnered with Fresenius Kabi to supply Diprivan® injectable emulsion, USP to healthcare providers, helping to stabilize the long-term supply of a medication vital for COVID-19 patient care.
-
Fresenius Kabi Expands MicroVault® Packaging to include Simplist® Morphine Sulfate Injection, USP Ready-to-Administer Prefilled Syringes
6/23/2020
Fresenius Kabi Expands MicroVault ® Packaging to include Simplist ® Morphine Sulfate Injection, USP Ready-to-Administer Prefilled Syringes